Log in

Relevant bibliographies by topics / Blinatumomab / Journal articles

To see the other types of publications on this topic, follow the link: Blinatumomab.

Journal articles on the topic 'Blinatumomab'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Blinatumomab.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

&NA;. "Blinatumomab." Reactions Weekly &NA;, no. 1339 (2011): 12. http://dx.doi.org/10.2165/00128415-201113390-00033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Buie, Larry W., Joshua J. Pecoraro, Troy Z. Horvat, and Ryan J. Daley. "Blinatumomab." Annals of Pharmacotherapy 49, no. 9 (2015): 1057–67. http://dx.doi.org/10.1177/1060028015588555.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Chen, Yun-Hsiang, Yun Wang, Cheng-Hao Liao та Shu-Ching Hsu. "The potential of adoptive transfer of γ9δ2 T cells to enhance blinatumomab’s antitumor activity against B-cell malignancy". Scientific Reports 11, № 1 (2021). http://dx.doi.org/10.1038/s41598-021-91784-1.

Full text

Abstract:

AbstractBlinatumomab, a bispecific T cell engager (BiTE) antibody targeting CD19 and CD3ε, can redirect T cells toward CD19-positive tumor cells and has been approved to treat relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). However, chemotherapeutic regimens can severely reduce T cells’ number and cytotoxic function, leading to an inadequate response to blinatumomab treatment in patients. In addition, it was reported that a substantial portion of R/R B-ALL patients failing blinatumomab treatment had the extramedullary disease, indicating the poor ability of blinatumomab in

APA, Harvard, Vancouver, ISO, and other styles

4

"Blinatumomab." Reactions Weekly 1854, no. 1 (2021): 87. http://dx.doi.org/10.1007/s40278-021-95418-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

"Blinatumomab." Reactions Weekly 1840, no. 1 (2021): 91. http://dx.doi.org/10.1007/s40278-021-90234-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

"Blinatumomab." Reactions Weekly 1837, no. 1 (2021): 115. http://dx.doi.org/10.1007/s40278-021-88714-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

"Blinatumomab." Reactions Weekly 1843, no. 1 (2021): 82. http://dx.doi.org/10.1007/s40278-021-91184-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

"Blinatumomab." Reactions Weekly 1847, no. 1 (2021): 101. http://dx.doi.org/10.1007/s40278-021-92658-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

"Blinatumomab." Reactions Weekly 1846, no. 1 (2021): 64. http://dx.doi.org/10.1007/s40278-021-92312-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

"Blinatumomab." Reactions Weekly 1925, no. 1 (2022): 131. http://dx.doi.org/10.1007/s40278-022-23908-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

"Blinatumomab." Reactions Weekly 1925, no. 1 (2022): 130. http://dx.doi.org/10.1007/s40278-022-23907-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

"Blinatumomab." Reactions Weekly 1858, no. 1 (2021): 85. http://dx.doi.org/10.1007/s40278-021-96803-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

"Blinatumomab." Reactions Weekly 1872, no. 1 (2021): 101. http://dx.doi.org/10.1007/s40278-021-02027-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

"Blinatumomab." Reactions Weekly 1866, no. 1 (2021): 96. http://dx.doi.org/10.1007/s40278-021-99792-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

"Blinatumomab." Reactions Weekly 1867, no. 1 (2021): 92. http://dx.doi.org/10.1007/s40278-021-00152-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

"Blinatumomab." Reactions Weekly 1863, no. 1 (2021): 77. http://dx.doi.org/10.1007/s40278-021-98681-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

"Blinatumomab." Reactions Weekly 1889, no. 1 (2022): 90. http://dx.doi.org/10.1007/s40278-022-08769-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

"Blinatumomab." Reactions Weekly 1873, no. 1 (2021): 55. http://dx.doi.org/10.1007/s40278-021-02478-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

"Blinatumomab." Reactions Weekly 1876, no. 1 (2021): 85. http://dx.doi.org/10.1007/s40278-021-03334-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

"Blinatumomab." Reactions Weekly 1864, no. 1 (2021): 81. http://dx.doi.org/10.1007/s40278-021-99011-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

"Blinatumomab." Reactions Weekly 1864, no. 1 (2021): 80. http://dx.doi.org/10.1007/s40278-021-99010-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

"Blinatumomab." Reactions Weekly 1896, no. 1 (2022): 93. http://dx.doi.org/10.1007/s40278-022-10884-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

"Blinatumomab." Reactions Weekly 2034, no. 1 (2024): 77. http://dx.doi.org/10.1007/s40278-024-70450-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

"Blinatumomab." Reactions Weekly 2027, no. 1 (2024): 97. http://dx.doi.org/10.1007/s40278-024-67286-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

"Blinatumomab." Reactions Weekly 2030, no. 1 (2024): 102. http://dx.doi.org/10.1007/s40278-024-68903-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

"Blinatumomab." Reactions Weekly 2030, no. 1 (2024): 101. http://dx.doi.org/10.1007/s40278-024-68902-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

"Blinatumomab." Reactions Weekly 2018, no. 1 (2024): 94. http://dx.doi.org/10.1007/s40278-024-63553-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

"Blinatumomab." Reactions Weekly 2018, no. 1 (2024): 93. http://dx.doi.org/10.1007/s40278-024-63552-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

"Blinatumomab." Reactions Weekly 2020, no. 1 (2024): 105. http://dx.doi.org/10.1007/s40278-024-64470-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

"Blinatumomab." Reactions Weekly 2033, no. 1 (2024): 62. http://dx.doi.org/10.1007/s40278-024-70172-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

"Blinatumomab." Reactions Weekly 2010, no. 1 (2024): 88. http://dx.doi.org/10.1007/s40278-024-59930-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

"Blinatumomab." Reactions Weekly 1960, no. 1 (2023): 108. http://dx.doi.org/10.1007/s40278-023-40936-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

"Blinatumomab." Reactions Weekly 1693, no. 1 (2018): 103. http://dx.doi.org/10.1007/s40278-018-42993-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

"Blinatumomab." Reactions Weekly 1695, no. 1 (2018): 73. http://dx.doi.org/10.1007/s40278-018-43900-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

"Blinatumomab." Reactions Weekly 1695, no. 1 (2018): 74. http://dx.doi.org/10.1007/s40278-018-43901-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

"Blinatumomab." Reactions Weekly 1710, no. 1 (2018): 70. http://dx.doi.org/10.1007/s40278-018-48743-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

"Blinatumomab." Reactions Weekly 1631, no. 1 (2016): 41. http://dx.doi.org/10.1007/s40278-016-23819-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

"Blinatumomab." Reactions Weekly 1636, no. 1 (2017): 60. http://dx.doi.org/10.1007/s40278-017-25620-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

"Blinatumomab." Reactions Weekly 1639, no. 1 (2017): 66. http://dx.doi.org/10.1007/s40278-017-26363-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

"Blinatumomab." Reactions Weekly 1645, no. 1 (2017): 63. http://dx.doi.org/10.1007/s40278-017-28145-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

"Blinatumomab." Reactions Weekly 1645, no. 1 (2017): 64. http://dx.doi.org/10.1007/s40278-017-28146-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

"Blinatumomab." Reactions Weekly 1685, no. 1 (2018): 41. http://dx.doi.org/10.1007/s40278-018-40900-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

"Blinatumomab." Reactions Weekly 1824, no. 1 (2020): 71. http://dx.doi.org/10.1007/s40278-020-84039-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

"Blinatumomab." Reactions Weekly 1815, no. 1 (2020): 80. http://dx.doi.org/10.1007/s40278-020-81406-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

"Blinatumomab." Reactions Weekly 1817, no. 1 (2020): 86. http://dx.doi.org/10.1007/s40278-020-82045-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

"Blinatumomab." Reactions Weekly 1836, no. 1 (2021): 186. http://dx.doi.org/10.1007/s40278-021-88005-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

"Blinatumomab." Reactions Weekly 1837, no. 1 (2021): 115. http://dx.doi.org/10.1007/s40278-021-88714-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

"Blinatumomab." Reactions Weekly 1726, no. 1 (2018): 96. http://dx.doi.org/10.1007/s40278-018-53735-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

"Blinatumomab." Reactions Weekly 1818, no. 1 (2020): 63. http://dx.doi.org/10.1007/s40278-020-82343-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

"Blinatumomab." Reactions Weekly 1473, no. 1 (2013): 10. http://dx.doi.org/10.1007/s40278-013-6401-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!